Caxton Associates (New York)’s Avanos Medical AVNS Stock Holding History

Caxton Associates (New York)’s Portfolio AVNS Stock Details AVNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-8,612	Closed	-$207K	–	500
2024 Q3	$207K	Sell	8,612 -8,423	-49%	-$193K	0.01%	483
2024 Q2	$339K	Buy	17,035 +2,034	+14%	+$39.6K	0.01%	391
2024 Q1	$299K	Sell	15,001 -16,418	-52%	-$317K	0.02%	385
2023 Q4	$705K	Buy	31,419 +7,147	+29%	+$148K	0.04%	272
2023 Q3	$491K	Buy	+24,272	New	+$550K	0.07%	249
2023 Q2	–	Sell	-10,633	Closed	-$316K	–	497
2023 Q1	$316K	Sell	10,633 -2,475	-19%	-$71.9K	0.05%	343
2022 Q4	$355K	Buy	13,108 +2,048	+19%	+$50.1K	0.02%	300
2022 Q3	$241K	Buy	+11,060	New	+$289K	0.03%	366

Other funds holding AVNS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

RGM Capital Naples, Florida $2.06B AUM 8.49% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

PIM

Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return

WHG

Westwood Holdings Group Dallas, Texas $13.7B AUM 21.48% 1-Year Est. Return

Caxton Associates (New York)'s AVNS Position: Q4 2024 in Review

Caxton Associates (New York) sold out of Avanos Medical (AVNS) in Q4 2024, closing a stake of 8,612 shares — an estimated $207K sold.

Caxton Associates (New York) first reported a position in AVNS in Q3 2022 and held it in 8 quarters. The position peaked at $705K in Q4 2023. 258 funds tracked by Wall St. Rank hold AVNS as of Q4 2024.

Caxton Associates (New York) reported no remaining Avanos Medical position as of Q4 2024 after selling out during the quarter.
Caxton Associates (New York) sold 8,612 Avanos Medical shares in Q4 2024, an estimated $207K.
Caxton Associates (New York) first reported a position in Avanos Medical in Q3 2022 and held it in 8 quarters.
Caxton Associates (New York)'s Avanos Medical position peaked at $705K in Q4 2023.
258 funds tracked by Wall St. Rank held Avanos Medical as of Q4 2024.

Based on Caxton Associates (New York)'s 13F filing for Q4 2024, filed 14 Feb 2025.